Next 10 |
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
2024-06-24 16:02:26 ET More on NeuroSense Therapeutics NeuroSense Therapeutics sheds 6% on $4.5M direct private offering Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information ...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...
2024-06-21 17:02:09 ET More on NeuroSense Therapeutics NeuroSense Therapeutics sheds 6% on $4.5M direct private offering Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information ...
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative ...
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit PR Newswire CAMBRIDGE, Mass. , ...
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PR Newswire PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass. ...
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...